VivoSim Labs (VIVS) Competitors

CASI Pharmaceuticals (NASDAQ:CASI) and VivoSim Labs (NASDAQ:VIVS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership.

Which has more volatility and risk, CASI or VIVS?

CASI Pharmaceuticals has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Comparatively, VivoSim Labs has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500.

Do analysts recommend CASI or VIVS?

CASI Pharmaceuticals currently has a consensus price target of $4.00, suggesting a potential upside of 233.33%. Given CASI Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe CASI Pharmaceuticals is more favorable than VivoSim Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
VivoSim Labs	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Is CASI or VIVS more profitable?

CASI Pharmaceuticals has a net margin of -129.05% compared to VivoSim Labs' net margin of -1,725.00%. VivoSim Labs' return on equity of -46.87% beat CASI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-129.05%	-972.55%	-77.33%
VivoSim Labs	-1,725.00%	-46.87%	-28.62%

Do insiders & institutionals hold more shares of CASI or VIVS?

22.2% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are owned by institutional investors. 21.2% of CASI Pharmaceuticals shares are owned by insiders. Comparatively, 3.7% of VivoSim Labs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Which has better earnings & valuation, CASI or VIVS?

VivoSim Labs has lower revenue, but higher earnings than CASI Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than VivoSim Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$28.54M	0.52	-$39.26M	-$2.55	-0.47
VivoSim Labs	$140K	27.30	-$2.48M	-$10.20	-0.14

Does the media prefer CASI or VIVS?

In the previous week, CASI Pharmaceuticals and CASI Pharmaceuticals both had 1 articles in the media. CASI Pharmaceuticals' average media sentiment score of 1.87 equaled VivoSim Labs'average media sentiment score.

Company	Overall Sentiment
CASI Pharmaceuticals	Very Positive
VivoSim Labs	Very Positive

Summary

CASI Pharmaceuticals beats VivoSim Labs on 8 of the 14 factors compared between the two stocks.